AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer

Recruitingn/aAges 18 Years - anyAllJรธrgen Bjerggaard Jensen
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Aim: To investigate the feasibility and tolerability of the Olympus Soltive laser in treatment of large recurrent low-grade Ta tumours in an outpatient setting. Background: Non-muscle invasive bladder cancer (NMIBC) is associated with a high yearly recurrence rate up to to 61%. Patients affected are therefore referred to long-term or even life-long follow-up, which burdens both patients and health care system. Recurrent tumours are most frequently treated with TURBT followed by adjuvant intravesical treatment. Repeat TURBT includes a risk of morbidity from the procedure itself and from general anaesthetics, which the procedure requires. Patients with NMIBC are generally elderly, multi-morbid, and as a result, they often show a poor tolerability of general anaesthetics. Thus, the need for non-surgical treatment modalities is imminent and continuous investigations are performed in the fie

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * At least one tumour with a diameter \> 1 cm * Papillary/non-solid tumours * Previous low-grade NMIBC * Ability to understand the participant information orally and in writing, in Danish, Spanish, Czech or French respectively * Signed consent form Exclusion Criteria: * Tumour diameter \> 3cm * Tumour in the prostatic urethra * Previous CIS, high-grade disease or muscle invasive bladder cancer with no later low-grade recurrence * Positive cytology within 3 months (testing not mandatory in patients with low-grade tumours) * Pregnancy
๐Ÿ’Š

What it tests

  • Laser ablation
๐Ÿ“

Where

1 site
Aarhus University Hospital
Aarhus, Denmark
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy